Mammogen Appoints Renowned Leadership Architect Denise "DeeDee" DeMan as Chairwoman of the Board

Strategic Insights -

Mammogen, a women-built and women-led predictive health company, has announced the appointment of Denise "DeeDee" DeMan as Chairwoman of its Board of Directors. DeMan, Founder, Chair, and CEO of Bench International, brings over five decades of experience in placing board directors, chairpersons, and C-level executives for global healthcare companies. Her appointment reflects Mammogen's evolution from a research-stage innovator to a clinical-stage company preparing for commercialization, as it advances its blood-based early detection test for breast cancer towards market launch.

Key Takeaways:

  • Denise "DeeDee" DeMan, a renowned leadership architect with over five decades of experience, has been appointed as Chairwoman of Mammogen's Board of Directors.
  • DeMan's appointment reflects Mammogen's transition from a research-stage innovator to a clinical-stage company, preparing for commercialization of its blood-based early detection test for breast cancer.
  • The test, genTRU (TM), has demonstrated over 99% sensitivity and 89% specificity for Stage I disease, supported by several peer-reviewed publications and extensive clinical validation.
  • DeMan's expertise in building governance and leadership for companies that endure is invaluable as Mammogen prepares for its next stage of growth.
  • The company is preparing for commercialization as the world's first and most accurate targeted screening test for breast cancer, addressing an urgent unmet need for over 25 million U.S. women currently at-risk based on Mammography Quality Standards Act (MQSA) Guidelines.
  • Mammogen's mission is to preserve quality of life through earlier, more accessible detection powered by cutting-edge science.

Statistics:

  • Over 99% sensitivity and 89% specificity for Stage I disease have been demonstrated by the genTRU (TM) assay.
  • Mammogen's blood-based early detection test for breast cancer has undergone several peer-reviewed publications and extensive clinical validation.
  • Over 25 million U.S. women are currently at-risk based on Mammography Quality Standards Act (MQSA) Guidelines.
  • Mammogen has a highly experienced leadership team, with Denise "DeeDee" DeMan and Elizabeth Cormier-May, CEO, driving the company's growth and innovation.
  • Bench International, DeMan's company, has a 98% project completion rate and a track record of over $150 billion in client exits.

Sources:

  • "Mammogen Appoints Renowned Leadership Architect Denise "DeeDee" DeMan as Chairwoman of the Board" (Mammogen)
  • Mammogen (Company website)
  • Bench International (Company website)